We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




New Glioma Test Provides Answers during Surgical Procedures

By LabMedica International staff writers
Posted on 13 Aug 2018
Print article
A new diagnostic test detects certain mutations in glioma tumors during brain surgery and identifies those sensitive to metabolic chemotherapeutic agents.

A glioma is a type of tumor that starts in the glial cells of the brain or the spine. Gliomas comprise about 30% of all brain tumors and central nervous system tumors, and 80% of all malignant brain tumors. Lower-grade gliomas are often characterized by mutations in the metabolism-related genes IDH1 (isocitrate dehydrogenase 1) and IDH2 (isocitrate dehydrogenase 2). Patients with glioma carrying mutations in either IDH1 or IDH2 have a relatively favorable survival, compared with patients with glioma with wild-type IDH1/2 genes.

Treating brain cancer and preventing recurrence has proven to be difficult, as the blood-brain barrier represents a considerable hurdle. To get around the blood brain barrier issue, investigators at Brigham and Women's Hospital (Boston, MA, USA), Massachusetts General Hospital (Boston, USA) and the Massachusetts Institute of Technology (Cambridge, MA, USA) hypothesized that application of metabolism-altering therapeutics at the surgical margin would improve tumor control and minimize toxicity. To facilitate this process, they developed an intraoperative diagnostic assay to identify IDH mutations.

The rapid multiplexed genotyping tool they developed was used to analyze previously collected patient samples. Results demonstrated that the assay could detect mutations within 27 minutes. For 75 of the 87 clinically annotated brain tumor specimens tested, the assay detected the presence of one or more mutations.

"The first and perhaps most important step in treatment of brain tumors is the initial operation, or craniotomy, which obtains tissue to make the diagnosis, and, for lower grade lesions, provides a therapeutic benefit from removal of the tumor mass," said senior author Dr. Daniel Cahill, associate professor of neurosurgery at Massachusetts General Hospital. "Prior studies from our group, and others, have shown that aggressive surgery provides a substantial survival benefit for patients with lower-grade gliomas. We sought to build upon this surgical scenario, attempting to further prolong survival for these patients."

The glioma diagnostic test was described in the August 6, 2018, online edition of the journal Proceedings of the National Academy of Sciences of the United States of America.

Related Links:
Brigham and Women's Hospital
Massachusetts General Hospital
Massachusetts Institute of Technology
Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.